e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The effect of HIV-associated tuberculosis, tuberculosis-IRIS and prednisone on lung function
Cari Stek, Brian Allwood, Elsa Du Bruyn, Jozefien Buyze, Charlotte Schutz, Friedrich Thienemann, Adele Lombard, Robert J. Wilkinson, Graeme Meintjes, Lutgarde Lynen
Source:
Eur Respir J, 55 (3) 1901692; 10.1183/13993003.01692-2019
Journal Issue:
March
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Cari Stek, Brian Allwood, Elsa Du Bruyn, Jozefien Buyze, Charlotte Schutz, Friedrich Thienemann, Adele Lombard, Robert J. Wilkinson, Graeme Meintjes, Lutgarde Lynen. The effect of HIV-associated tuberculosis, tuberculosis-IRIS and prednisone on lung function. Eur Respir J, 55 (3) 1901692; 10.1183/13993003.01692-2019
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
The effect of prednisone treatment on lung function test parameters in patients with chronic sarcoidosis
Source: Eur Respir J 2002; 20: Suppl. 38, 433s
Year: 2002
The effect of long term low dose azithromycin on symptoms and lung function in pulmonary sarcoidosis
Source: Annual Congress 2008 - Sarcoidosis: pathophysiology and severity
Year: 2008
The efficacy of treatment with surfactant-BL (S-BL) in patients with destructive pulmonary tuberculosis
Source: Annual Congress 2007 - Research perspectives: diagnosis and treatment of tuberculosis
Year: 2007
The impact of long-term azithromycin on antibiotic resistance in HIV-associated chronic lung disease
Source: ERJ Open Res, 8 (1) 00491-2021; 10.1183/23120541.00491-2021
Year: 2022
Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis
Source: Eur Respir J 2011; 38: 1145-1150
Year: 2011
The course of COVID-19 in pulmonary sarcoidosis patients, receiving methotrexate
Source: Virtual Congress 2021 – Moving forward in various aspects of sarcoidosis
Year: 2021
The effect of antituberculosis chemotherapy on thyroid hormones in active pulmonary tuberculosis patients
Source: Eur Respir J 2001; 18: Suppl. 33, 306s
Year: 2001
Efficiency of standard chemotherapy of patients with pulmonary TB with relapses and treatment failure at drug resistance of M. tuberculosis
Source: Eur Respir J 2001; 18: Suppl. 33, 339s
Year: 2001
Pulmonary disease caused by M. malmoense in HIV negative patients: 5-yr follow-up of patients receiving standardised treatment
Source: Eur Respir J 2003; 21: 478-482
Year: 2003
COVID19 coinfection exacerbates lung inflammation in TB patients.
Source: Virtual Congress 2021 – Tuberculosis, COVID-19 and other comorbidities
Year: 2021
Long-term response to prednisone in newly treated patients with pulmonary sarcoidosis
Source: Virtual Congress 2021 – Better understanding of sarcoidosis: new keys
Year: 2021
Extrapulmonary tuberculosis in patients with chronic kidney disease receiving renal replacement therapy
Source: International Congress 2019 – Tuberculosis and comorbidities
Year: 2019
Serious infections in sarcoidosis and the effect of treatment
Source: International Congress 2019 – Granulomatous disorders: from bench to bedside
Year: 2019
Effect of low dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): results from a real life study
Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Year: 2021
Lung function defects in treated pulmonary tuberculosis patients
Source: Eur Respir J 2016; 47: 351-352
Year: 2016
Lung function defects in treated pulmonary tuberculosis patients
Source: Eur Respir J 2016; 47: 352-353
Year: 2016
The factors associated to pulmonary impairment in patients with treated tuberculosis
Source: Annual Congress 2012 - Tuberculosis: clinical findings III
Year: 2012
Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment
Source: International Congress 2016 – IPF treatment I
Year: 2016
Long-term lung function follow-up in patients diagnosed and treated for pulmonary tuberculosis
Source: Annual Congress 2010 - Prognosis of tuberculosis
Year: 2010
Effect of infliximab on lung function and well-being in patients with refractory sarcoidosis
Source: Annual Congress 2011 - Different profiles of sarcoidosis and other granulomatous disorders
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept